Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

WS Management Raised Stake in $CHMT

WS Management filed a 13G on October 26th, indicating that it has boosted its stake in Chemtura Corp (CHMT) to 4.89 million shares, or a 5.072% passive stake. Since WS Management revealed 2 million shares in its last 13F filing, this is a 245% expansion in its position. CHMT filed bankruptcy and its reorganization was confirmed in November 2010. The stock has lost nearly 30% year to date. On October 4th, it dropped to its historical low. Probably WS Management entered at about $10 when the uptrend was shaped. Now CHMT is trading at $12.70.

Chemtura Corp (NYSE:CHMT)

CHMT was in thirty nine hedge funds in the second quarter. Joshua Friedman And Mitchell Julis’ Canyon Capital Advisors retained 5.68 million shares, or 5.8% stake. David Gallo’s Valinor Management reported 2.79 million shares, giving it a 2.85% stake. Malcolm Fairbairn’s Ascend Capital had 2.28 million shares, or a 2.33% stake at that time.

WS Management is a private company in Jacksonville, FL. The firm is categorized under Management Investment Open-End. Current estimates show this company has a $98,000 annual revenue.

According to the company biography from its bankruptcy settlement, Chemtura Corp is “a global, diversified producer of specialty chemicals, polymer products, and crop protection chemicals, and is a leading U.S. supplier of pool and spa chemicals. The majority of Chemtura’s chemical products are sold to industrial manufacturing customers for use as additives, ingredients, or intermediates to add value to their end products”.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!